Teflaro ceftaroline fosamil regulatory update

FDA accepted for review an sNDA from Actavis to expand the label of Teflaro ceftaroline to treat cases of concurrent bacteremia in patients with acute bacterial skin and skin structure infections (ABSSSIs) caused by Staphylococcus aureus. The PDUFA date is in 3Q15; a specific date was not disclosed. ...